https://doi.org/10.4081/reumatismo.2019.1115
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
Submitted: 31 December 2017
Accepted: 6 September 2018
Published: 9 July 2019
Accepted: 6 September 2018
Abstract Views: 1127
PDF: 705
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
How to Cite
Shobha, V., Desai, A., & Matthew, T. (2019). Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo, 71(2), 99–102. https://doi.org/10.4081/reumatismo.2019.1115
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- M. Ruggiero, A. Conforti, A. Culcasi, C. Mazzanti, G. Sibahi, N. Rani, S. Sartini, A focus on melorheostosis disease: a literature review and case report of femoral-acetabular impingement due to melorheostosis treated with surgical hip osteoplasty , Reumatismo: Vol. 76 No. 1 (2024)
- G. Carlino, P. Trande, M. Muratore, E. De Micheli, G. Santacesaria, Chronic osteomyelitis: a new therapeutical idea , Reumatismo: Vol. 53 No. 4 (2001)
- C. Grava, A. Ruffatti, O. Milanesi, M. Favaro, M. Tonello, A. Calligaro, T. Del Ross, S. Todesco, Isolated congenital heart block in undifferentiated connective tissue disease and in primary Sjögren’s syndrome: a clinical study of 81 pregnancies in 41 patients , Reumatismo: Vol. 57 No. 3 (2005)
- D.D. Gladman, BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS , Reumatismo: Vol. 59 No. s1 (2007)
- R. Peluso, M. Atteno, S. Iervolino, V. Bruner, F. Caso, L. Costa, M. Raimodo, M. Lofrano, F. Manguso, R. Scarpa, Methotrexate in the treatment of peripheral arthritis in ulcerative colitis , Reumatismo: Vol. 61 No. 1 (2009)
- C. Tani, M. Mosca, A. d'Ascanio, R. Neri, A. Tavoni, L. Carli, S. Bombardieri, Long term outcome of treatment of diffuse proliferative glomerulonephritis with pulse steroids and short course pulse cyclophosphamide , Reumatismo: Vol. 62 No. 3 (2010)
- C. Nalli, L. Andreoli, M. Motta, G.L. Norman, Z. Shums, W.L. Binder, M. Nuzzo, M. Frassi, A. Lojacono, A. Meini, V. Medeghini, T. Avcin, P.L. Meroni, A. Tincani, Fine specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1 , Reumatismo: Vol. 63 No. 2 (2011)
- A.S. Hammami, M. Jellazi, S. Arfa, S. Daada, K. Ben Hamda , A. Achour, S. Ouali, Getting to the heart of the matter: diagnostic tools and therapeutic approach to cardiac involvement in Behçet syndrome A Tunisian case series , Reumatismo: Vol. 73 No. 1 (2021)
- G. Frosi, A. Sulli, M. Testa, M. Cutolo, The sterno-clavicular joint: anatomy, biomechanic, clinical features and aspects of manual therapy , Reumatismo: Vol. 56 No. 2 (2004)
- L. Andreoli, F. Pregnolato, R.W. Burlingame, V. Fanelli, F. Allegri, A. Radice, C. Corace, R.A. Sinico, A. Tinconi, P.L. Meroni, Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? , Reumatismo: Vol. 60 No. 3 (2008)
<< < 25 26 27 28 29 30 31 32 33 34 > >>
You may also start an advanced similarity search for this article.
